1346146-72-2

Upstream product

• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 
• 1262859-53-9 4-bromo-1-fluoro-2-isopropenyl-benzene 
• 1346146-67-5 (RS)-4-bromo-1-fluoro-2-(2-iodo-1-isocyanato-1-methyl-ethyl)-benzene 
• 1346146-69-7 (RS)-4-(5-bromo-2-fluoro-phenyl)-4-methyl-oxazolidin-2-one 
• 112204-57-6 dihydroxy-(5-bromo-2-fluorophenyl)-borane 

Downstream Products

• 1266785-96-9 (R)-2-(5-bromo-2-fluoro-phenyl)-2-(4-methoxy-benzylamino)-propan-1-ol 
• 1228571-14-9 (2R)-2-amino-2-(5-bromo-2-fluorophenyl)propan-1-ol 
• 1346146-75-5 (R)-3-(5-bromo-2-fluoro-phenyl)-3-methyl-[1,4]oxazepan-5-one 
• 1346146-77-7 (R)-3-[5-(benzhydrylidene-amino)-2-fluoro-phenyl]-3-methyl-[1,4]oxazepan-5-one 
• 1346146-78-8 (R)-3-(5-amino-2-fluoro-phenyl)-3-methyl-[1,4]oxazepan-5-one hydrochloride 
• 1346146-79-9 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [4-fluoro-3-((R)-3-methyl-5-oxo-[1,4]oxazepan-3-yl)phenyl]amide 
• 1346146-82-4 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [3-((R)-5-ethoxy-3-methyl-2,3,6,7-tetrahydro-[1,4]oxazepin-3-yl)-4-fluorophenyl]amide 
• 1266785-98-1 [(R)-1-(5-bromo-2-fluoro-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)-1-methyl-ethyl]-(4-methoxy-benzyl)-amine 
• 1346147-60-1 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [3-((R)-5-amino-3-methyl-2,3,6,7-tetrahydro-[1,4]oxazepin-3-yl)-4-fluoro-phenyl]amide 
• 1346146-73-3 N-[(R)-1-(5-bromo-2-fluoro-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)-1-methyl-ethyl]-3-chloro-N-(4-methoxy-benzyl)-propionamide 
• 1346146-74-4 (R)-3-(5-bromo-2-fluoro-phenyl)-4-(4-methoxy-benzyl)-3-methyl-[1,4]oxazepan-5-one 

Relevant academic research and scientific papers

Palladium-Catalyzed Enantioselective Synthesis of Cyclic Sulfamidates and Application to a Synthesis of Verubecestat

An enantioselective arylation reaction catalyzed by palladium complexed with substituted phosphinooxazoline (PHOX) ligands is described. Aza-quaternary stereocenters are readily accessible through the arylation reaction between cyclic iminosulfates and a wide variety of arylboronic acids, including electron-poor and ortho-substituted arylboronic acids. This reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of Alzheimer's disease.

1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention provides 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present

2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS

This invention relates to compounds of the formula (I), wherein A, B and R1 to R7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as 5 medicam

2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS

This invention relates to compounds of the formula wherein A, B and R1 to R7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments fo